Vulvovaginitis: Clinical Trials

6 trials for Vulvovaginitis, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

6 completed. 6 Phase 1, 1 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 16Completed 6
Phase 21Completed 1

Follow Vulvovaginitis: new trials by email Literature Review of Vulvovaginitis trials Research Report on Vulvovaginitis

Trials (filtered) newest first · largest first

All 6 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Safety and Tolerability Studies of CanProFem-AK, Vaginal Suppositories in Healthy Volunteers
CanProFem-AK - Candidosis Vaginal
Phase 1CompletedIndustrial Microbiology LLP202024-06-012024-08-02
Pharmacokinetic Study in Healthy Lactating Women Exposed to Ibrexafungerp
Ibrexafungerp - Vulvovaginal Candidiasis, Candida Infection
Phase 1CompletedScynexis, Inc.52023-07-122025-08-08
Study Evaluating the Optimal Dosage for Equivalence Between Lcr Regenerans® Capsules and Tablets (Lactobacillus Rhamnosus Lcr35®) on the Vaginal Flora Colonisation
Lcr Regenerans® vaginal capsules, Lcr Regenerans® vaginal tablet - Candidiasis, Vulvovaginal
Phase 1CompletedBiose342015-07-012018-02-05
Safety, Tolerability, Immunogenicity and Efficacy of NDV-3A Vaccine in Preventing Recurrent Vulvovaginal Candidiasis
NDV-3A, NDV-3, Placebo - Vulvovaginal Candidiasis
Phase 1 / Phase 2CompletedNovaDigm Therapeutics, Inc.1882013-07-012018-07-18
Evaluation of Intravaginal Gel and Ovule Formulations of TOL-463
TOL-463 Vaginal ovule, TOL-463 Vaginal gel - Vaginal Infection
Phase 1CompletedNational Institute of Allergy and Infectious Diseases (NIAID)262013-04-012014-05-16
Safety and Immunogenicity Study of a Virosomal Vaccine Against Recurrent Vulvovaginal Candida Infection
PEV7C1, PEV7C9, PEV7B2 - Recurrent Vulvovaginal Candidiasis
Phase 1CompletedPevion Biotech Ltd482010-03-012012-12-24

Narrower conditions

Candidiasis, Vulvovaginal (6)  ·  Candidiasis (2)  ·  Mycoses (2)  ·  Torulopsis (2)  ·  Candidiasis, Oral (1)  ·  Vaginitis (1)  ·  Vaginosis, Bacterial (1)

Broader conditions

Bacterial Infections and Mycoses (6)  ·  Female Urogenital Diseases (6)  ·  Female Urogenital Diseases and Pregnancy Complications (6)  ·  Genital Diseases (6)  ·  Genital Diseases, Female (6)  ·  Infections (6)  ·  Urogenital Diseases (6)  ·  Vaginal Diseases (6)  ·  Vulvar Diseases (6)  ·  Vulvitis (6)  ·  Vaginitis (5)  ·  Candidiasis (4)  ·  Mycoses (4)  ·  Bacterial Infections (1)

Interventions

ibrexafungerp (1)

Sponsors

Biose (1)  ·  Industrial Microbiology LLP (1)  ·  National Institute of Allergy and Infectious Diseases (NIAID) (1)  ·  NovaDigm Therapeutics, Inc. (1)  ·  Pevion Biotech Ltd (1)  ·  Scynexis, Inc. (1)

Countries

United States (3)  ·  France (1)  ·  Kazakhstan (1)  ·  Switzerland (1)

Top investigators

Giuseppe Pantaleo, Prof (1)  ·  John P. Hennessey, Jr., Ph.D. (1)  ·  Rolf Pokorny, MD, MSc (1)

Results publications

PMID 29697768

NIH funding

2014 (1)